ORIGINAL INVESTIGATION. Effect of Smoking Cessation on Mortality After Myocardial Infarction
|
|
- Elisabeth Gregory
- 5 years ago
- Views:
Transcription
1 Effect of Smoking Cessation on Mortality After Myocardial Infarction Meta-analysis of Cohort Studies ORIGIL INVESTIGATION Kumanan Wilson, MD, MSc, FRCPC; Neil Gibson, MD, MSc, FRCPC; Andrew Willan, PhD; Deborah Cook, MD, MSc, FRCPC Objective: To determine the effect of smoking cessation on mortality after myocardial infarction. Data Sources: English- and non English-language articles published from 1966 through 1996 retrieved using keyword searches of MEDLINE and EMBASE supplemented by letters to authors and searching bibliographies of reviews. Study Selection: Selection of relevant abstracts and articles was performed by 2 independent reviewers. Articles were chosen that reported the results of cohort studies examining mortality in patients who quit vs continued smoking after myocardial infarction. Data Extraction: Mortality data were extracted from the selected articles by 2 independent reviewers. Data Synthesis: Twelve studies were included containing data on 5878 patients. The studies took place in 6 countries between 1949 and Duration of follow-up ranged from 2 to 10 years. All studies showed a mortality benefit associated with smoking cessation. The combined odds ratio based on a random effects model for death after myocardial infarction in those who quit smoking was 0.54 (95% confidence interval, ). Relative risk reductions across studies ranged from 15% to 61%. The number needed to quit smoking to save 1 life is 13 assuming a mortality rate of 20% in continuing smokers. The mortality benefit was consistent regardless of sex, duration of followup, study site, and time period. Conclusion: Results of several cohort studies suggest that smoking cessation after myocardial infarction is associated with a significant decrease in mortality. Arch Intern Med. 2000;160: From the Departments of Medicine (Drs Wilson, Gibson, and Cook) and Clinical Epidemiology and Biostatistics (Drs Wilson, Gibson, Willan, and Cook), McMaster University, Hamilton, Ontario. SMOKING IS the leading preventable cause of premature death in the United States and is responsible for more than deaths annually. 1 Many of these smoking-related deaths occur in patients with cardiac disease. Individuals with ischemic heart disease who smoke are at particular risk for increased mortality due to the adverse effects of cigarettes on coronary blood flow, myocardial oxygen demand, and risk of thrombosis. 2-7 These effects seem to be reversible, and significant reductions in mortality have been observed in patients with established cardiovascular disease who quit smoking. 8 Rigorous randomized trials 9-11 have focused on the effect of smoking cessation programs on cessation rates in patients after myocardial infarction (MI) and after coronary bypass surgery. One trial 12 of nicotine replacement therapy vs placebo in patients with stable coronary artery disease examined the effect on cardiac events (death, MI, cardiac arrest, hospital admission for angina, arrhythmia, or congestive heart failure) and found no significant difference. A randomized trial to specifically examine the question of whether individuals who quit smoking after MI have a lower mortality rate than those who continue smoking would require allocating patients to a continuing smoking arm. Because this is not practical, investigators have instead relied on cohort studies to obtain evidence on this issue. These cohort studies have consistently demonstrated improvements in mortality associated with smoking cessation, although the benefits have been variable. We performed a meta-analysis of these cohort studies to determine a more precise estimate of the mortality benefit associated with smoking cessation after MI. We also examined whether this effect was present in several subgroups. RESULTS STUDY SELECTION The MEDLINE and EMBASE search strategy yielded 605 citations that included 13 potentially relevant articles ,20-24,26,29 One additional article 19 was obtained from a ref- 939
2 MATERIALS AND METHODS LITERATURE SEARCH We conducted a search of English- and non Englishlanguage articles in the MEDLINE database between January 1966 and September 1996 using the following strategy. Exp smoking or exp smoking cessation was cross-referenced with MI and the following prognosis terms: incidence or exp mortality or mortality(sh [subject heading]) or exp follow-up studies or prognos:(tw [text word]) or predict(tw) or cohort studies or course:(tw) or prognosis or natural(tw) and history(tw). We also performed a similar search of the EMBASE database. We chose keywords for prognosis studies that have been demonstrated to maximize sensitivity for detecting sound clinical studies in this area. 27 In addition, references from review articles were searched and letters were sent to authors of selected studies requesting information about other relevant unpublished material. ELIGIBILITY CRITERIA Two of us (K.W. and N.G.) independently evaluated the MEDLINE and EMBASE abstracts of each article and the retrieved articles (foreign-language articles were reviewed by only one individual). Articles selected for the metaanalysis had to meet the following criteria: (1) study of patients after MI, (2) determination of smoking status at the time of MI and any time thereafter, (3) at least 1 year of follow-up, (4) reporting of mortality rates in those who quit and those who continued smoking, and (5) enrollment of at least 100 patients. For selection of MEDLINE and EMBASE abstracts, both reviewers were masked to the author, journal, and year of publication. All disagreement was resolved by consensus, and statistics were used to evaluate chance-corrected agreement. QUALITY ASSESSMENT We examined the articles selected for review to determine their quality. Articles were assigned scores using the following criteria (fully meets criteria, partially meets criteria, does not meet criteria): (1) Was a representative, well-defined sample of patients identified (2, 1, 0)? (2) Were patients enrolled consecutively (2, 1, 0)? (3) Were there clear definitions of MI (1, 0.5, 1) and smoking status at time of enrollment (1, 0.5, 1)? (4) Was there an objective, valid assessment of smoking status at follow-up (biological verification) (2, 1, 0)? (5) Was follow-up complete ( 90%) (2, 1, 0)? (6) Was there adjustment for important prognostic factors (2, 1, 0)? The maximum score for an article is 10. DATA ALYSIS In duplicate, we independently extracted data from the relevant articles. Data regarding mortality in smokers and nonsmokers were abstracted as the primary outcome. Further information was obtained regarding location and year of trial, sex and age of the study population, time of assessment of smoking status, duration of follow-up, and effect of age and infarct size on mortality. Before combining the results, we performed a test for homogeneity. We compared mortality rates in continuing smokers and the cessation group using odds ratios. We calculated odds ratios for the individual studies and a combined odds ratio using a DerSimonion and Laird random effects model. 28 We also ordered the studies according to quality score to examine if quality was associated with magnitude of effect. We examined the mortality benefit associated with smoking cessation in the following prespecified subgroups: sex, study period (enrollment before or after 1980), duration of follow-up (10 years or 10 years), and country of study. These analyses were conducted to determine whether the benefit was present in different populations (sex) or was affected by temporal or geographical differences in management or differences in medical therapies (study period and country of study) and whether the effect persisted over time (duration of follow-up). We performed a study-level regression analysis to determine whether sex, duration of follow-up, study period, or quality of study affected the effect size. 28 We also examined the distribution of certain prognostic factors between continuing smokers and those who quit. erence of a review. Of these 14 articles, 2 were excluded: an early follow-up of a previously identified article 26 and a duplicate report. 29 Kappa scores for agreement on abstracts and final articles were 0.79 and 0.65, respectively, suggesting a substantial level of agreement. 30 STUDY CHARACTERISTICS Twelve studies involving 5878 patients were included in the final analysis (Table 1). The studies were conducted in 6 countries: Ireland, United States, Finland, Sweden, United Kingdom, and Norway. The earliest study 14 enrolled patients beginning in 1949, and the latest study 24 accrued patients from 1986 to Four studies examined men only, 13,15,17,20 1 examined women only, 19 and 7 examined a mixed population. 14,16,18,21-24 Time of assessment of smoking status ranged from 1 month to 1 year after MI, with 2 studies having ongoing assessment of smoking status. 14,18 Duration of follow-up ranged from 2 to 10 years. Smoking cessation rates in these studies ranged from 29% to 74%. EFFECT ON MORTALITY A lower mortality rate was associated with smoking cessation in all studies (Table 2). Odds ratios ranged from 0.29 to 0.84, and the combined odds ratio was 0.54 (95% confidence interval [CI], ). Four studies had 95% CIs that included The Zelen test for homogeneity was not significant (P =.61), suggesting that the differences in the results of the individual studies were compatible with chance. The estimate of between-study variance was negative. Consequently, the combined odds ratio and 95% CI using a random effects model were identical to those of a fixed effects model (odds ratio, 0.54; 95% CI, ) (Figure). 940
3 Table 1. Benefit of Smoking Cessation on Mortality After Myocardial Infarction: Results of the Primary Studies* Study Years of Enrollment Time of Assessment Follow-up, y Cessation Rate, % ARR (RRR), % Mulcahy et al, (Ireland) mo (36) Sparrow et al, (US) Every 2 y (38) Salonen, (Finland) mo (41) Rodda, (Norway) mo (15) Aberg et al, (Sweden) mo (37) Perkins and Dick, (UK) mo, 12 mo, every year (61) Johansson et al, (Sweden) mo (52) Burr et al, (UK) 1980s 6 mo (57) Hedback et al, (Sweden) y (31) Tofler et al, (US) mo (51) Herlitz et al, (Sweden) y (45) Greenwood et al, (UK) mo (24) *ARR indicates absolute risk reduction; RRR, relative risk reduction; US, United States; and UK, United Kingdom. Assessment of smoking status. Subgroup analysis from a randomized controlled trial. Table 2. Benefit of Smoking Cessation: Crude Rates and Odds Ratios* Smoking Cessation Group Continued Smoking Group Study Deaths, No. Total Enrolled, No. Rate, % Deaths, No. Total Enrolled, No. Rate, % Odds Ratio (95% CI) Mulcahy et al, ( ) Sparrow et al, ( ) Salonen, ( ) Rodda, ( ) Aberg et al, ( ) Perkins and Dick, ( ) Johansson et al, ( ) Burr et al, ( ) Hedback et al, ( ) Tofler et al, ( ) Herlitz et al, ( ) Greenwood et al, ( ) Combined odds ratio (95% CI) 0.54 ( ) *CI indicates confidence interval. Subgroup analysis from a randomized controlled trial. Mortality rates in the cessation group ranged from 4% to 37% and in continuing smokers from 8% to 54%. Relative risk reductions ranged from 15% to 61%, with 10 of 12 studies having values greater than 30%. Absolute risk reductions ranged from 1.2% to 27.5%. Based on an odds ratio of 0.54 and an estimated mortality rate of 20% in continuing smokers, the number needed to quit smoking to save one life is approximately Mean duration of follow-up adjusted for study size was 4.8 years. The number needed to treat compares favorably with those for other therapeutic interventions. 32 QUALITY OF THE PRIMARY STUDIES Quality scores for the primary studies ranged from 6.5 to8(table 3). Three of the included studies 16,20,22 were subgroups of randomized controlled trials. All of the studies had a well-defined sample of patients. Five studies 13,15,17,19,20 restricted patients by sex; most had age restrictions (usually enrolling patients 65 years old). All studies either attempted to enroll consecutive patients or had a Patients, Study Year No. Mulcahy et al Sparrow et al Salonen Rodda Aberg et al Perkins and Dick Johannson et al Burr et al Hedback et al Tofler et al Herlitz et al Greenwood et al Overall 5878 Favors Smoking Cessation Favors Continued Smoking Odds Ratio (95% CI) Odds ratios and 95% confidence intervals (CIs) using a random effects model for reduction in mortality associated with smoking cessation after myocardial infarction. Asterisk indicates subgroup analysis from a randomized controlled study. systematic method for inclusion (eg, including every other male 65 years old). One study 24 relied on response to a questionnaire for smoking cessation data and had a 45% response rate. 941
4 Table 3. Quality Assessment of Primary Studies* Study Well-Defined Sample (2) Consecutive Entries of Patients (2) Smoking Status Clearly Defined (1) MI Clearly Defined (1) Follow-up, % (2) Objective Assessment of Smoking Status (2) Difference in Baseline Factors Accounted for (2) Total Score (10) Mulcahy et al, Yes Yes Yes Yes 100 No No 7 Sparrow et al, Yes Yes Yes Yes 97 No No 7 Salonen, Yes Yes Yes Yes 99 No Yes 8 Rodda, Yes Yes Yes Yes 100 No No 7 Aberg et al, Yes Partial (1) Yes Yes 100 Partial (1) Yes 8 Perkins and Dick, Yes Yes Yes Yes 97 No Yes 8 Johansson et al, Yes Partial (1) Yes Yes 100 No Yes 7 Burr et al, Yes Yes Yes Yes 100 No Yes 8 Hedback et al, Yes Partial (1) Partial (0.5) Yes 100 No Yes 6.5 Tofler et al, Yes Yes Yes Yes 100 No No 8 Herlitz et al, Yes Yes Yes Yes 100 No Yes 8 Greenwood et al, Yes Yes Yes Yes 100 No Yes 7 *MI indicates myocardial infarction. Numbers in parentheses indicate value for category if criteria fully met. Table 4. Subgroup Analyses* Variable and Study No. of Studies No. of Patients The definition of an MI was consistent across studies, requiring some combination of chest pain, electrocardiographic changes, and increase in cardiac enzyme levels. The definition of smoking status was more variable; however, most studies required smoking at least 1 cigarette per day. Smokingstatusdependedonself-reportinallbutonestudy, 17 which biochemically verified smoking status on a subgroup of patients. Three studies described some form of smoking cessation counseling. Nine of 12 studies 14,15,17-21,23,24 examined the differences in age and infarct size in continuing smokers vs those who quit. In all 10 studies 13,14,16-21,23,24 in which information on follow-up could be obtained, follow-up was greater than 90%. SUBGROUP ALYSES Odds Ratio (95% CI) Country United States 14, ( ) Ireland ( ) United Kingdom 18,20, ( ) Norway ( ) Sweden 17,19,21, ( ) Finland ( ) Year study conducted Before , ( ) After , ( ) Follow-up, y 10 17, ( ) ,18-20, ( ) Sex Male 13,15,17,18,20, ( ) Female 18, ( ) *CI indicates confidence interval. The mortality benefit was noted in all of the subgroups (Table 4). The odds ratio for mortality in women was 0.36 (95% CI, ) and in men was 0.52 (95% CI, ). However, several studies 14,16,22-24 did not present data separately for men and women. Eight studies enrolled patients before ,21 and 4 enrolled patients after ,22-24 The respective odds ratios (95% CIs) were 0.55 ( ) and 0.52 ( ). Two studies reported extended follow-up of 10 years. 17,21 The combined odds ratio for these studies was 0.54 (95% CI, ). The odds ratio for the shorter follow-up studies was 0.53 (95% CI, ). Odds ratios for country of study ranged from 0.49 (United States, 2 studies with 897 patients) 14,22 to 0.84 (Norway, 1 study with 918 patients). 16 The study-level regression analysis illustrated that none of the following factors affected the combined odds ratio: sex (P =.16), year of study (P =.85), duration of follow-up (P =.87), and quality of study (P =.92). DISTRIBUTION OF CONFOUNDING VARIABLES BETWEEN CONTINUING SMOKERS AND THOSE WHO QUIT SMOKING Nine studies 14,15,17-21,23,24 considered the effect of age on mortality rates. Only one of these studies 23 noted that continuing smokers were significantly older. In the study by Greenwood et al, 24 adjustment for age increased the observed mortality benefit associated with smoking cessation (reduction in the odds ratio from 0.71 to 0.58 ). Four studies 15,17,19,23 considered the effect of infarct size. These studies primarily used peak enzyme rise or evidence of congestive heart failure to evaluate the size of the infarct. No study relied on left ventricular ejection fraction to quantitate infarct size. Of these 4 studies, 3 of them 15,17,19 suggested that the patients who quit smoking had larger infarcts, and the other study 23 showed no differences between the groups (Table 5). Several studies also reported the distribution of cardiac risk factors between those who continued smoking and those who quit. Two studies 14,17 noted that ex-smokers were more likely to be diabetic than were those who continued smoking, and one study 15 observed no difference. Three studies 14,17,18 observed that continuing smokers had lower mean blood pressure, one 23 observed that they had a higher mean blood pressure, and another 21 showed no differ- 942
5 ence. One study 14 found that continuing smokers had lower mean cholesterol levels. Two studies 14,18 found that continuing smokers had lower mean weights. In no instance were the differences statistically significant. COMMENT The mortality benefit of smoking cessation on mortality after MI observed in our meta-analysis is of moderate to large magnitude and is consistent across study location, patient sex, time periods, and different durations of followup. The results are consistent with the mortality benefits observed in smoking cessation studies 8,33,34 of patients after coronary artery bypass surgery, after angioplasty, and with stable coronary artery disease. The odds ratio of 0.54 in this study compares favorably with odds ratios from meta-analyses of other MI interventions. In comparison, the odds ratio for reduction in mortality after MI for thrombolytic therapies is 0.75 (95% CI, ), for aspirin after MI is 0.77 (95% CI, ), and for -blockers after MI is 0.88 (95% CI, ). 35 These odds ratios are from meta-analyses of randomized controlled trials, which generally have higher validity than do cohort studies in determining treatment effects and tend to show smaller effect sizes. 36,37 The degree of heterogeneity in this meta-analysis was surprisingly low. This might be explained by the fact that the primary studies were all of approximately the same validity and used consistent methods. The lack of heterogeneity adds further support to the observed mortality benefit associated with smoking cessation after MI. The results of the study-level regression analysis were not surprising as there was no heterogeneity to explain. Caution is appropriate in interpreting the results of this meta-analysis because the results are based on data from cohort studies. Lack of randomization in these studies increases the likelihood of there being unequal distribution of important prognostic variables. We examined the effect of age and infarct size as potential confounding variables in the primary studies and found that in studies that took these factors into account, they did not seem to bias the results. Mechanisms for evaluating infarct size were not optimal, however. We cannot exclude the possibility that other significant variables might be unequally distributed across smoking and nonsmoking groups, biasing the results of this metaanalysis. Individuals who quit smoking might have other changes in behavior that could provide them with a survival advantage. It is also possible that these individuals received more effective MI management than did those who continued smoking. The latter issue is made less likely by the observation that the mortality benefit was present before 1980 when use of most modern post-mi therapies was not routine. Former smokers might also have smoked fewer cigarettes, on average, before the infarct than continuing smokers, conferring on them a survival advantage. A major methodological concern was the accuracy of self-report of smoking status because only one study 17 used biological confirmation. Misrepresentation of smoking status rates based on self-report have been found to be as high as 26% after MI. 38 For this potential Table 5. Differences in Age and Infarct Size Between Continuing Smokers and Those Who Quit Smoking After Myocardial Infarction* Study Age Infarct Size Mulcahy et al, Sparrow et al, Ex-smokers were younger Salonen, No effect on results No effect on results Rodda, Aberg et al, Ex-smokers were older Ex-smokers had larger infarcts Perkins and Dick, No significant difference Johansson et al, No significant difference Ex-smokers had larger infarcts Burr et al, No significant difference Hedback et al, Ex-smokers were older Tofler et al, Herlitz et al, Ex-smokers were younger No significant difference in CHF Greenwood et al, Ex-smokers were older * indicates not assessed; CHF, congestive heart failure. As determined by cardiac enzyme tests and evidence of CHF. bias to inflate the effect size, the assumption would have to be made that those who misrepresented themselves as nonsmokers have a better chance of surviving. Only 2 of 12 studies 14,18 had ongoing assessment of smoking status. This could potentially bias the results against the benefit of smoking cessation if individuals changed their smoking status after the time of assessment. Previous reviews of smoking cessation after MI have found that although most relapses occur within the first 3 months, relapses do occur after 1 year. 39 Publication bias also could potentially affect the results of this meta-analysis. Randomized trials of MI therapies, in particular, may have examined smoking subgroups and chosen not to publish the subgroup results if no important interaction was noted. We attempted to identify any relevant unpublished material by contacting authors in the field. Two published abstracts 40,41 that were not associated with full manuscripts were found, and both reported large reductions in mortality associated with cessation of smoking that were consistent with the results of our meta-analysis. The large fail-safe N of 241 (the number of null result studies that would need to be added to the meta-analysis to produce a nonsignificant result) makes it unlikely that there would be enough unpublished data to counter the effect found in this meta-analysis. 42 This meta-analysis provides compelling evidence for the benefit of smoking cessation on mortality in patients after MI. Given the magnitude of this mortality benefit, even modest reductions in smoking rates in this patient population might translate into a significant decrease in the number of deaths. The results of this metaanalysis and other studies 11,43,44 suggest that the development of cardiac disease itself is a strong stimulus to induce smoking cessation. Attempts have been made to increase cessation rates using smoking cessation pro- 943
6 grams. However, randomized trials 9-11 examining the benefits of these programs in patients with cardiovascular disease have yielded mixed results. Use of nicotine replacement therapy in patients with stable cardiac disease has also been studied 12,45 and, although seeming not to have any adverse effects, has not been demonstrated to induce long-term cessation. More randomized trials of smoking cessation interventions in patients with cardiovascular disease are warranted. Ideally, these trials will have extended follow-up and examine effects on cardiovascular events, mortality, and cessation rates. Accepted for publication June 29, We thank John Attia, Roman Jaeschke, and Phillip Tschopp for their assistance with translation of foreignlanguage articles. Reprints: Kumanan Wilson, MD, MSc, FRCPC, Civic Parkdale Clinic, 737 Parkdale Ave, Suite 414, Ottawa, Ontario, Canada K1Y 1J8 ( REFERENCES 1. Peto R, Lopez AD, Boreham J, Thun M, Heath C Jr, Doll RI. Mortality from smoking worldwide. Br Med Bull. 1996;52: Cryer PE, Haymond MW, Santiago JV, Shah SD. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N Engl J Med. 1976;295: Quillen JE, Rossen JD, Oskarsson HJ, Minor RL Jr, Lopez JAG, Winniford MD. Acute effect of cigarette smoking on the coronary circulation: constriction of epicardial and resistance vessels. J Am Coll Cardiol. 1993;22: Kannel WB, D Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and the risk of cardiovascular disease: insights from the Framingham Study. Am Heart J. 1987;113: Meade TW, Imeson J, Stirling Y. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. Lancet. 1987;2: Schmidt KG, Rasmussen JW. Acute platelet activation induced by smoking: in vivo and ex vivo studies in humans. Thromb Haemost. 1984;51: Benowitz NL, Fitzgerald GA, Wilson M, Zhang Q. Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking. J Am Coll Cardiol. 1993;22: Hermanson B, Omenn GS, Kronmal RA, Gersh BJ. Beneficial six-year outcome of smoking cessation in older men and women with coronary artery disease: results from the CASS registry. N Engl J Med. 1988;319: Taylor CB, Houston-Miller N, Killen JD, DeBusk RF. Smoking cessation after myocardial infarction: effects of a nurse-managed intervention. Ann Intern Med. 1990; 113: Taylor CB, Houston-Miller N, Haskell WL, Debusk RF. Smoking cessation after acute myocardial infarction: the effects of exercise training. Addict Behav. 1988; 13: Rigotti N, McKool KM, Shiffman S. Predictors of smoking cessation after coronary artery bypass graft surgery: results of a randomized trial with 5-year followup. Ann Intern Med. 1994;120: Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996; 335: Mulcahy R, Hickey N, Graham IM, MacAirt J. Factors affecting the 5 year survival rate of men following acute coronary heart disease. Am Heart J. 1977;93: Sparrow D, Dawber TR, Colton T. The influence of cigarette smoking on prognosis after a first myocardial infarction: a report from the Framingham Study. J Chronic Dis. 1978;31: Salonen JT. Stopping smoking and long-term mortality after acute myocardial infarction. Br Heart J. 1980;43: Rodda BE. The Timolol Myocardial Infarction Study: an evaluation of selected variables. Circulation. 1983;67(suppl I):I101-I Aberg A, Bergstrand R, Johansson S, et al. Cessation of smoking after myocardial infarction: effects on mortality after 10 years. Br Heart J. 1983;49: Perkins J, Dick TB. Smoking and myocardial infarction: secondary prevention. Postgrad Med J. 1985;61: Johansson S, Bergstrand R, Pennert K, et al. Cessation of smoking after myocardial infarction in women: effects on mortality and reinfarctions. Am J Epidemiol. 1985;121: Burr ML, Holliday RM, Fehily AM, Whitehead PJ. Haematological prognostic indices after myocardial infarction: evidence from the Diet and Reinfarction Trial (DART). Eur Heart J. 1992;13: Hedback B, Perk J, Wodlin P. Long-term reduction of cardiac mortality after myocardial infarction: 10-year results of a comprehensive rehabilitation programme. Eur Heart J. 1993;14: Tofler GH, Muller JE, Stone PH, Davies G, Davis VG, Braunwald E. Comparison of long-term outcome after acute myocardial infarction in patients never graduated from high school with that in more educated patients. Am J Cardiol. 1993; 71: Herlitz J, Bengston A, Hjalmarson A, Karlson BW. Smoking habits in consecutive patients with acute myocardial infarction: prognosis in relation to other risk indicators and to whether or not they quit smoking. Cardiology. 1995;86: Greenwood DC, Muir KR, Packham CJ, Madeley RJ. Stress, social support, and stopping smoking after myocardial infarction in England. J Epidemiol Community Health. 1995;49: Mulcahy R, Hickey N, Graham I, McKenzie G. Factors influencing long-term prognosis in male patients surviving first coronary attack. Br Heart J. 1975;37: Wilhelmsson C, Vedin JA, Elmfeldt D, Tibblin G, Wilhelmsen L. Smoking and myocardial infarction. Lancet. 1975;1: Haynes RB, Wilczynski N, McKibbon KA, Walker CJ, Sinclair JC. Developing optimal search strategies for detecting clinically sound studies in MEDLINE. J Am Med Inform Assoc. 1994;1: Raudenbush SW. Random effects models. In: Cooper H, Hedges LV, eds. The Handbook of Research Synthesis. New York, NY: Russell Sage Foundation; Ronnevik PK, Gundersen T, Abrahamsen AM. Effect of smoking habits and timolol treatment on mortality and reinfarction in patients surviving acute myocardial infarction. Br Heart J. 1985;54: Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33: Sackett DL, Deeks JJ, Altman DG. Down with odds ratios [editorial]. Evidence- Based Med. 1996;1: McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 1997;126: Voors AA, Van Brussel BL, Plokker T, et al. Smoking and cardiac events after venous coronary bypass surgery. Circulation. 1996;93: Hasdai D, Garrat KN, Grill DE, Lerman A, Holmes DR Jr. Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. N Engl J Med. 1997;336: Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med. 1992;327: Chalmers TC, Celano P, Sacks HS, Smith H Jr. Bias in treatment assignment in controlled clinical trials. N Engl J Med. 1983;309: Miller JN, Colditz GA. How study design affects outcomes in comparisons of therapy, II: surgical. Stat Med. 1989;8: Wilcox RG, Hughes J, Roland J. Verification of smoking history in patients after infarction using urinary nicotine and cotinine measurements. BMJ. 1979;2: Perkins KA. Maintaining smoking abstinence after myocardial infarction. J Subst Abuse. 1988;1: Pohjola S, Siltanen P, Roma M, Haapakoski J. Effect of quitting smoking on the long-term survival after myocardial infarction. Trans Eur Soc Cardiol. 1979;1:2. Abstract Goldberg R, Szklo M, Chandra V. The effect of cigarette smoking on the longterm prognosis of myocardial infarction [abstract]. Am J Epidemiol. 1981;114: Julian JA. Summary Odds Ratios for 2X2Xk Tables (Version 1.0) [software]. Hamilton, Ontario: McMaster University. 43. Burling TA, Singleton EG, Bigelow GE, Baile WF, Gottlieb SH. Smoking following myocardial infarction: a critical review of the literature. Health Psychol. 1984;3: Rigotti, Singer DE, Mulley AG, Thibault GE. Smoking cessation following admission to a coronary care unit. J Gen Intern Med. 1991;6: Working group for the study of transdermal nicotine in patients with coronary artery disease. Nicotine replacement therapy for patients with coronary artery disease. Arch Intern Med. 1994;154:
Registration and management of smoking behaviour in patients with coronary heart disease
European Heart Journal (1999) 20, 1630 1637 Article No. euhj.1999.1635, available online at http://www.idealibrary.com on Registration and management of smoking behaviour in patients with coronary heart
More informationDownloaded from irje.tums.ac.ir at 13:07 IRST on Friday March 8th 2019
CI: Boa Winbugs NCSS Meta-regression akbarzad@sbmu.ac.ir Electronic Search MEDLINE, EMBASE Irandoc, IranMedex, SID, Science Citation Index coronary prospective cohort smoking cessation heart disease studies
More informationJournal of the American College of Cardiology Vol. 36, No. 3, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 36, No. 3, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00810-X Smoking
More informationNicotine Dependence and Smoking Cessation after Hospital Discharge among Inpatients with Coronary Heart Attacks
[Environmental Health and Preventive Medicine 7, 74 78, May 2002] Original Article Nicotine Dependence and Smoking Cessation after Hospital Discharge among Inpatients with Coronary Heart Attacks Atsuhiko
More informationEvidence Supporting Post-MI Use of
Addressing the Gap in the Management of Patients After Acute Myocardial Infarction: How Good Is the Evidence Supporting Current Treatment Guidelines? Michael B. Fowler, MB, FRCP Beta-adrenergic blocking
More informationCessation of smoking after myocardial infarction
Br Heart J 1983; 49: 416-22 Cessation of smoking after myocardial infarction Effects on mortality after 10 years ANDERS ABERG, ROBERT BERGSTRAND, SAGA JOHANSSON, GORAN ULVENSTAM, ANDERS VEDIN, HANS WEDEL,
More informationSmoking and CVD. .what role for the Cardiologist? Dr Sandeep Gupta, MD, FRCP
Smoking and CVD.what role for the Cardiologist? Dr Sandeep Gupta, MD, FRCP Consultant Cardiologist Whipps Cross/BartsHealth NHS Trusts Hospitals, London, UK Therapeutic Advances in the Treatment of Cardiovascular
More informationLow fractional diastolic pressure in the ascending aorta increased the risk of coronary heart disease
(2002) 16, 837 841 & 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Low fractional diastolic pressure in the ascending aorta increased the risk
More informationInter-regional differences and outcome in unstable angina
European Heart Journal (2000) 21, 1433 1439 doi:10.1053/euhj.1999.1983, available online at http://www.idealibrary.com on Inter-regional differences and outcome in unstable angina Analysis of the International
More informationRisk Factors for Ischemic Stroke: Electrocardiographic Findings
Original Articles 232 Risk Factors for Ischemic Stroke: Electrocardiographic Findings Elley H.H. Chiu 1,2, Teng-Yeow Tan 1,3, Ku-Chou Chang 1,3, and Chia-Wei Liou 1,3 Abstract- Background: Standard 12-lead
More informationClopidogrel has been evaluated in clinical trials that included cardiovascular patients
REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,
More informationPatient characteristics Intervention Comparison Length of followup
ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing
More informationThe Clinical Case for Smoking Cessation for CARDIOVASCULAR PATIENTS
The Clinical Case for Smoking Cessation for CARDIOVASCULAR PATIENTS What is this initiative aiming to achieve? The aim of this initiative is to provide clinical support for temporary abstinence with a
More informationEffect of intravenous atropine on treadmill stress test results in patients with poor exercise capacity or chronotropic incompetence ABSTRACT
Effect of intravenous atropine on treadmill stress test results in patients with poor exercise capacity or chronotropic incompetence Samad Ghaffari, MD, Bahram Sohrabi, MD. ABSTRACT Objective: Exercise
More informationSmoking Cessation: Good News at Last!
Smoking Cessation: Good News at Last! Andrew L. Pipe, CM, MD The Minto Prevention & Rehabilitation Centre University of Ottawa Heart Institute Ottawa, Ontario. Canada apipe@ottawaheart.ca Declaration of
More informationBiases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University
Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of
More informationOutline. What is Evidence-Based Practice? EVIDENCE-BASED PRACTICE. What EBP is Not:
Evidence Based Practice Primer Outline Evidence Based Practice (EBP) EBP overview and process Formulating clinical questions (PICO) Searching for EB answers Trial design Critical appraisal Assessing the
More informationEnhancing Retrieval of Best Evidence for Health Care from Bibliographic Databases: Calibration of the Hand Search of the Literature
Enhancing Retrieval of Best Evidence for Health Care from Bibliographic Databases: Calibration of the Hand Search of the Literature Nancy L. Wilczynski a, K. Ann McKibbon a, R. Brian Haynes a a Health
More informationImpaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events
Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationJournal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL
More informationSmoking Cessation Interventions In Hospital Settings: Implementing the Evidence
Smoking Cessation Interventions In Hospital Settings: Implementing the Evidence Nancy Rigotti, MD Tobacco Research & Treatment Center, General Medicine Division, Massachusetts General Hospital, Harvard
More informationCardiovascular disease and varenicline (Champix)
Cardiovascular disease and varenicline (Champix) 2013 National Centre for Smoking Cessation and Training (NCSCT). Version 3: August 2013. Authors: Leonie S. Brose, Eleni Vangeli, Robert West and Andy McEwen
More informationOutcomes assessed in the review
The effectiveness of mechanical compression devices in attaining hemostasis after removal of a femoral sheath following femoral artery cannulation for cardiac interventional procedures Jones T Authors'
More informationClinical Policy Title: Cardiac rehabilitation
Clinical Policy Title: Cardiac rehabilitation Clinical Policy Number: 04.02.02 Effective Date: September 1, 2013 Initial Review Date: February 19, 2013 Most Recent Review Date: February 6, 2018 Next Review
More informationSerum cholesterol and long-term prognosis in middle-aged men with myocardial infarction and angina pectoris
European Heart Journal (1997) 18, 754-761 Serum cholesterol and long-term prognosis in middle-aged men with myocardial and angina pectoris A 16-year follow-up of the Primary Prevention Study in Goteborg,
More informationEmotional distress in patients with coronary heart disease
Reducing Emotional Distress Improves Prognosis in Coronary Heart Disease 9-Year Mortality in a Clinical Trial of Rehabilitation Johan Denollet, PhD; Dirk L. Brutsaert, MD Background The impact of treating
More informationPredictors of smoking cessation among Chinese parents of young children followed up for 6 months
Title Predictors of smoking cessation among Chinese parents of young children followed up for 6 months Author(s) Abdullah, ASM; Lam, TH; Loke, AY; Mak, YW Citation Hong Kong Medical Journal, 2006, v. 12
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL A Meta-analysis of LDL-C, non-hdl-c, and apob as markers of cardiovascular risk. Slide # Contents 2 Table A1. List of candidate reports 8 Table A2. List of covariates/model adjustments
More informationClinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center
Aging Research Volume 2013, Article ID 471026, 4 pages http://dx.doi.org/10.1155/2013/471026 Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at
More informationChoice of axis, tests for funnel plot asymmetry, and methods to adjust for publication bias
Technical appendix Choice of axis, tests for funnel plot asymmetry, and methods to adjust for publication bias Choice of axis in funnel plots Funnel plots were first used in educational research and psychology,
More informationQ. Qiao 1, M. Tervahauta 2, A. Nissinen 2 and J. Tuomilehto 1. Introduction
European Heart Journal (2000) 21, 1621 1626 doi:10.1053/euhj.2000.2151, available online at http://www.idealibrary.com on Mortality from all causes and from coronary heart disease related to smoking and
More informationJournal of the American College of Cardiology Vol. 35, No. 4, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 4, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00643-9 Early
More informationEXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
More informationCardiac Rehabilitation after Primary Coronary Intervention CONTRA
DEBATE SESSION Is there a role for cardiac rehabilitation in the modern era of Percutaneous coronary intervention and coronary artery bypass grafting? Cardiac Rehabilitation after Primary Coronary Intervention
More informationAcute Myocardial Infarction: Difference in the Treatment between Men and Women
Quality Assurance in Hcahh Can, Vol. 5, No. 3, pp. 261-265,1993 Printed in Great Britain 1040-6166/93 $6.00 + 0.00 1993 Pergamon Press Ltd Acute Myocardial Infarction: Difference in the Treatment between
More informationSubsequent management and therapies
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Subsequent management and therapies Marco Valgimigli, MD, PhD University of Ferrara ITALY
More informationT wave changes and postinfarction angina pectoris
Br Heart Y 1981; 45: 512-16 T wave changes and postinfarction angina pectoris predictive of recurrent myocardial infarction RURIK LOFMARK* From the Department of Medicine, Karolinska Institute at Huddinge
More informationSchool of Dentistry. What is a systematic review?
School of Dentistry What is a systematic review? Screen Shot 2012-12-12 at 09.38.42 Where do I find the best evidence? The Literature Information overload 2 million articles published a year 20,000 biomedical
More informationBiases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University
Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of
More informationHeart failure. Complex clinical syndrome. Estimated prevalence of ~2.4% (NHANES)
Heart failure Complex clinical syndrome caused by any structural or functional impairment of ventricular filling or ejection of blood Estimated prevalence of ~2.4% (NHANES) Etiology Generally divided into
More informationStatistical challenges of meta-analyses of randomised clinical trials in a regulatory setting
Statistical challenges of meta-analyses of randomised clinical trials in a regulatory setting Frank Pétavy ISCTM 14th Annual Scientific Meeting, Washington D.C. Presented by Frank Pétavy on 21 February
More informationSystematic Reviews and Meta- Analysis in Kidney Transplantation
Systematic Reviews and Meta- Analysis in Kidney Transplantation Greg Knoll MD MSc Associate Professor of Medicine Medical Director, Kidney Transplantation University of Ottawa and The Ottawa Hospital KRESCENT
More informationIssues in Meta-Analysis: An Overview
REVIEW Issues in Meta-Analysis: An Overview Alfred A. Bartolucci, Charles R. Katholi, Karan P. Singh, and Graciela S. Alarc6n A summary is provided for the relevant issues that investigators must address
More informationCost-effectiveness of brief intervention and referral for smoking cessation
Cost-effectiveness of brief intervention and referral for smoking cessation Revised Draft 20 th January 2006. Steve Parrott Christine Godfrey Paul Kind Centre for Health Economics on behalf of PHRC 1 Contents
More informationDiabetologia 9 Springer-Verlag 1991
Diabetologia (1991) 34:590-594 0012186X91001685 Diabetologia 9 Springer-Verlag 1991 Risk factors for macrovascular disease in mellitus: the London follow-up to the WHO Multinational Study of Vascular Disease
More informationExercise-Induced Silent Ischemia: Age, Diabetes Mellitus, Previous Myocardial Infarction and Prognosis
JACC Vol. 14, No. 5 November I. 1989:117.1-X0 1175 Exercise-Induced Silent Ischemia: Age, Diabetes Mellitus, Previous Myocardial Infarction and Prognosis PETER R. CALLAHAM, MD, VICTOR F. FROELICHER, MD,
More informationORIGINAL INVESTIGATION. Self-Selected Posttrial Aspirin Use and Subsequent Cardiovascular Disease and Mortality in the Physicians Health Study
ORIGINAL INVESTIGATION Self-Selected Posttrial Aspirin Use and Subsequent Cardiovascular Disease and Mortality in the Physicians Health Study Nancy R. Cook, ScD; Patricia R. Hebert, PhD; JoAnn E. Manson,
More informationThe problem of uncontrolled hypertension
(2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands
More informationMeta-analysen Methodik für Mediziner
Kardiolunch, 11.2.2014 Meta-analysen Methodik für Mediziner PD Dr Matthias Briel Basel Institute for Clin Epi & Biostats, Switzerland McMaster University, Hamilton, Canada Agenda SystematischeReviews &
More informationComparison of Probability of Stroke Between the Copenhagen City Heart Study and the Framingham Study
80 Comparison of Probability of Stroke Between the Copenhagen City Heart Study and the Framingham Study Thomas Truelsen, MB; Ewa Lindenstrtfm, MD; Gudrun Boysen, DMSc Background and Purpose We wished to
More informationTobacco-related deaths and disabilities are on
Nursing intervention and smoking cessation: A meta-analysis Virginia Hill Rice, PhD, RN, CS, FAAN, Detroit, Michigan OBJECTIVE: To determine with meta-analysis the effects of nursing-delivered smoking
More informationAssessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington
Assessing Cardiac Risk in Noncardiac Surgery Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Disclosure None. I have no conflicts of interest, financial or otherwise. CME
More informationNicotine replacement therapy to improve quit rates
Nicotine replacement therapy to improve quit rates Matrix Insight, in collaboration with Imperial College London, Kings College London and Bazian Ltd, were commissioned by Health England to undertake a
More informationAcute Coronary Syndrome. Sonny Achtchi, DO
Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification
More informationCritical Review Form Therapy Objectives: Methods:
Critical Review Form Therapy Clinical Trial Comparing Primary Coronary Angioplasty with Tissue-Plasminogen Activator for Acute Myocardial Infarction (GUSTO-IIb), NEJM 1997; 336: 1621-1628 Objectives: To
More informationSetting The setting was the Walter Reed Army Medical Center. The economic study was carried out in the USA.
Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Moran A, Zhao D, Gu D, et al. The Future Impact of Population
More informationDoes quality of life predict morbidity or mortality in patients with atrial fibrillation (AF)?
Does quality of life predict morbidity or mortality in patients with atrial fibrillation (AF)? Erika Friedmann a, Eleanor Schron, b Sue A. Thomas a a University of Maryland School of Nursing; b NEI, National
More informationRepeat ischaemic heart disease audit of primary care patients ( ): Comparisons by age, sex and ethnic group
Repeat ischaemic heart disease audit of primary care patients (2002-2003): Comparisons by age, sex and ethnic group Baseline-repeat ischaemic heart disease audit of primary care patients: a comparison
More informationSUPPLEMENTARY DATA. Supplementary Figure S1. Search terms*
Supplementary Figure S1. Search terms* *mh = exploded MeSH: Medical subject heading (Medline medical index term); tw = text word; pt = publication type; the asterisk (*) stands for any character(s) #1:
More informationStress ECG is still Viable in Suleiman M Kharabsheh, MD, FACC Consultant Invasive Cardiologist KFHI KFSHRC-Riyadh
Stress ECG is still Viable in 2016 Suleiman M Kharabsheh, MD, FACC Consultant Invasive Cardiologist KFHI KFSHRC-Riyadh Stress ECG Do we still need stress ECG with all the advances we have in the CV field?
More informationTime of onset and predictors of biphasic anaphylactic reactions: A systematic. A. To describe the time frame where biphasic reactions can occur.
KER UNIT - PROTOCOL OF REVIEW TITLE Time of onset and predictors of biphasic anaphylactic reactions: A systematic review and meta-analysis of the literature REVIEW QUESTION A. To describe the time frame
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationHospital and 1-year outcome after acute myocardial infarction in patients with diabetes mellitus and hypertension
(2003) 17, 665 670 & 2003 Nature Publishing Group All rights reserved 0950-9240/03 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Hospital and 1-year outcome after acute myocardial infarction in patients with
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationBody mass decrease after initial gain following smoking cessation
International Epidemiological Association 1998 Printed in Great Britain International Journal of Epidemiology 1998;27:984 988 Body mass decrease after initial gain following smoking cessation Tetsuya Mizoue,
More informationI t is established that regular light to moderate drinking is
32 CARDIOVASCULAR MEDICINE Taking up regular drinking in middle age: effect on major coronary heart disease events and mortality S G Wannamethee, A G Shaper... See end of article for authors affiliations...
More informationPlasma lipids can be reliably assessed within 24 hours after
Postgraduate Medical Journal (1988) 64, 352-356 Plasma lipids can be reliably assessed within 24 hours after acute myocardial infarction M. Sewdarsen, S. Vythilingum, I. Jialal* and R. Nadar Ischaemic
More informationHeart Failure and Cardiomyopathy Center, Division of Cardiology, North Shore University Hospital, Manhasset, NY
NEUROHORMONAL ANTAGONISTS IN THE POST-MI PATIENT New Evidence from the CAPRICORN Trial: The Role of Carvedilol in High-Risk, Post Myocardial Infarction Patients Jonathan D. Sackner-Bernstein, MD, FACC
More information1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES
1 Comparison of Ischemic and Bleeding Events After Drug- Eluting Stents or Bare Metal Stents in Subjects Receiving Dual Antiplatelet Therapy: Results from the Randomized Dual Antiplatelet Therapy (DAPT)
More informationNEWS ON ISCHEMIC HEART DISEASE AT THE ESC 2018 CONGRESS MARIO MARZILLI, MD, PhD
NEWS ON ISCHEMIC HEART DISEASE AT THE ESC 2018 CONGRESS MARIO MARZILLI, MD, PhD Author affiliations: Cardiovascular Medicine Division, Pisa University Medical School, Pisa, Italy Address for correspondence:
More informationJBI Database of Systematic Reviews & Implementation Reports 2014;12(2)
The effectiveness of reducing dietary sodium intake versus normal dietary sodium intake in patients with heart failure on reducing readmission rate: a systematic review protocol Palle Larsen 1,4 Preben
More informationTobacco Consumption and Acute Myocardial Infarction
Home SVCC Area: English - Español - Português Tobacco Consumption and Acute Myocardial Infarction Bianco, Eduardo; Cobas, Joaquín Cardiac Care Unit (CCU), Asociación Española Primera de Socorros Mutuos.
More informationStress, social support, and stopping smoking
J7ournal of Epidemiology and Community Health 1995;49:583587 Department of Public Health Medicine and Epidemiology, University Hospital, Queen's Medical Centre, Nottingham, NG7 2UH D C Greenwood K R Muir
More informationSMOKING STATUS AND LONG-TERM OUTCOME AFTER PERCUTANEOUS CORONARY REVASCULARIZATION
EFFECT OF SMOKING STATUS ON THE LONG-TERM OUTCOME AFTER SUCCESSFUL PERCUTANEOUS CORONARY REVASCULARIZATION DAVID HASDAI, M.D., KIRK N. GARRATT, M.D., DIANE E. GRILL, M.S., AMIR LERMAN, M.D., AND DAVID
More informationCost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) Study
Cost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) Study Andre Lamy, MD, MHSc; Salim Yusuf, DPhil; Janice Pogue, MSc; Amiram Gafni,
More informationStatin pretreatment and presentation patterns in patients with acute coronary syndromes
Brief Report Page 1 of 5 Statin pretreatment and presentation patterns in patients with acute coronary syndromes Marcelo Trivi, Ruth Henquin, Juan Costabel, Diego Conde Cardiovascular Institute of Buenos
More informationManagement of ST-elevation myocardial infarction Update 2009 Late comers: which options?
European Society of Cardiology Annual Session 2009 Management of ST-elevation myocardial infarction Update 2009 Late comers: which options? Antonio Abbate, MD Assistant Professor of Medicine Virginia Commonwealth
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Percutaneous access for endovascular aortic aneurysm repair: a systematic review and meta-analysis Shahin Hajibandeh, Shahab Hajibandeh,
More informationSystematic reviewers neglect bias that results from trials stopped early for benefit
Journal of Clinical Epidemiology 60 (2007) 869e873 REVIEW ARTICLE Systematic reviewers neglect bias that results from trials stopped early for benefit Dirk Bassler a,b, Ignacio Ferreira-Gonzalez a,c,d,
More informationSystematic reviews and meta-analyses of observational studies (MOOSE): Checklist.
Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. MOOSE Checklist Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:
More informationA Systematic Review and Meta-Analysis of Pre-Transfusion Hemoglobin Thresholds for Allogeneic Red Blood Cell Transfusions
A Systematic Review and Meta-Analysis of Pre-Transfusion Hemoglobin Thresholds for Allogeneic Red Blood Cell Transfusions Authors: Lesley J.J. Soril 1,2, MSc; Laura E. Leggett 1,2, MSc; Joseph Ahn, MSc
More informationTrials Enrolled subjects Findings Fox et al. 2014, SIGNIFY 1
Appendix 5 (as supplied by the authors): Published trials on the effect of ivabradine on outcomes including mortality in patients with different cardiovascular diseases Trials Enrolled subjects Findings
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationAmerican Journal of Internal Medicine
American Journal of Internal Medicine 2016; 4(3): 49-59 http://www.sciencepublishinggroup.com/j/ajim doi: 10.11648/j.ajim.20160403.12 ISSN: 2330-4316 (Print); ISSN: 2330-4324 (Online) The Effect of Dose-Reduced
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationSupplementary Online Material
Supplementary Online Material Collet T-H, Gussekloo J, Bauer DC, et al; Thyroid Studies Collaboration. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med.
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationCardiac evaluation for the noncardiac. Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology
Cardiac evaluation for the noncardiac patient Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology Objectives! Review ACC / AHA guidelines as updated for 2009! Discuss new recommendations
More informationDownloaded from:
Arnup, SJ; Forbes, AB; Kahan, BC; Morgan, KE; McKenzie, JE (2016) The quality of reporting in cluster randomised crossover trials: proposal for reporting items and an assessment of reporting quality. Trials,
More informationTraumatic brain injury
Introduction It is well established that traumatic brain injury increases the risk for a wide range of neuropsychiatric disturbances, however there is little consensus on whether it is a risk factor for
More informationThe Whitehall II study originally comprised 10,308 (3413 women) individuals who, at
Supplementary notes on Methods The study originally comprised 10,308 (3413 women) individuals who, at recruitment in 1985/8, were London-based government employees (civil servants) aged 35 to 55 years.
More informationSupplementary Online Content
Supplementary Online Content Li S, Chiuve SE, Flint A, et al. Better diet quality and decreased mortality among myocardial infarction survivors. JAMA Intern Med. Published online September 2, 2013. doi:10.1001/jamainternmed.2013.9768.
More informationAn Evolving Perspective on Smoking Cessation Therapies
An Evolving Perspective on Smoking Cessation Therapies Andrew Pipe, CM, MD Chief, Division of Prevention & Rehabilitation University of Ottawa Heart Institute Faculty/Presenter Disclosure Andrew Pipe,
More informationThe Healthy User Effect: Ubiquitous and Uncontrollable S. R. Majumdar, MD MPH FRCPC FACP
The Healthy User Effect: Ubiquitous and Uncontrollable S. R. Majumdar, MD MPH FRCPC FACP Professor of Medicine, Endowed Chair in Patient Health Management, Health Scholar of the Alberta Heritage Foundation,
More informationSmoking decreases the duration of life lived with and without cardiovascular disease: a life course analysis of the Framingham Heart Study
European Heart Journal (24) 25, 49 45 Clinical research Smoking decreases the duration of life lived with and without cardiovascular disease: a life course analysis of the Framingham Heart Study Abdullah
More informationStatins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 1 Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review. C ANYANWU, C NOSIRI Citation C ANYANWU, C NOSIRI.
More informationMeta-analysis of the implantable cardioverter defibrillator secondary prevention trials
European Heart Journal (2000) 21, 2071 2078 doi.10.1053/euhj.2000.2476, available online at http://www.idealibrary.com on Meta-analysis of the implantable cardioverter defibrillator secondary prevention
More information